You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
廣生堂(300436.SZ):聘毛偉忠為首席科學家兼首席開發官 全面負責公司全球創新藥臨牀開發與商業化運營
格隆匯 03-25 20:44

格隆匯3月25日丨廣生堂(300436.SZ)公佈,為更好實現公司向創新藥企業轉型的發展戰略,加快推進公司技術創新和產品升級,公司董事會同意聘任John Wei-Zhong Mao(毛偉忠)博士為公司首席科學家兼首席開發官,全面負責公司全球創新藥的臨牀開發與商業化運營。

主要職責為:制定公司在研創新藥的總體開發方案和計劃並指導開發過程、根據公司戰略發展需要推動新藥國際權益轉讓和引進創新藥國際戰略合作者等。本次毛偉忠博士出任公司首席科學家,有利於進一步完善公司產品研發團隊建設,將在推動公司的科技創新、高端技術人才培育等方面提升公司核心競爭力。

公告顯示,John Wei-Zhong Mao(毛偉忠)博士,美籍華人,復旦大學化學系學士國羅德島大學分析與生物分析化學理學碩士和博士,負責或參與了18個美國新藥臨牀試驗IND申請和2個新藥上市許可NDA申請,是擁有超過25年臨牀前、臨牀研究和新藥商業化生產經驗的生物製藥領域專家,曾擔任Foresee Pharmaceuticals(舊金山和台灣)高級副總裁和產品開發總負責人、Cytokinetics, Inc. (舊金山)非臨牀開發副總裁以及Praecis Pharmaceuticals(波士頓)、Idenix Pharmaceuticals (波士頓)高級管理職務。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account